Phase I Study of the BBP-398 in Patients With Advance Solid Tumors

Summary

This is an open label, dose escalation and expansion, two-part Phase I study for SHP-2 inhibitor BBP-398 to evaluate the safety, tolerability, pharmacokinetics, determine MTD and/or RP2D, and preliminary anti- cancer activity in Chinese subjects with advanced solid tumors and in Chinese subjects with advanced or metastatic EGFR-mutant NSCLC.

Timeline

Start

2022-10-18

Primary completion

2024-03-29

Completion

2024-03-29

Drugs

Indications